Indaptus Therapeutics, Inc.
INDP- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001857044
No open-market purchases or sales by Indaptus Therapeutics, Inc. insiders were filed in the last 90 days; 9 institutions reported holding it in 13F filings for Q2 2026, worth $1.15M in total; no superinvestor holds it.
Q4 2021 vs. Q3 2021
How the institutions holding Indaptus Therapeutics, Inc. changed between Q3 2021 and Q4 2021.
All holders in Q4 2021All holders in Q3 2021
| Measure | Q3 2021 | Q4 2021 | Change |
|---|---|---|---|
| Holders | 15 | 15 | 0 |
| Shares | 541.7K | 1.84M | +1.29M (+239.0%) |
| Value | $4.24M | $10.5M | +$6.23M (+146.8%) |
New holders (4)
Institutions that held Indaptus Therapeutics, Inc. at the end of Q4 2021 but not at the end of Q3 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Stratos Wealth Partners, LTD. | 1,388,356 | $7.91M | 0.18% |
| Millennium Management LLC | 38,040 | $217.0K | 0.00% |
| United Capital Financial Advisers, LLC | 15,000 | $86.0K | 0.00% |
| National Bank of Canada | 500 | $3.00K | 0.00% |
Sold out (4)
Institutions that held Indaptus Therapeutics, Inc. at the end of Q3 2021 and filed for Q4 2021 without it.
| Institution | Shares, Q3 2021 | Value, Q3 2021 |
|---|---|---|
| Armistice Capital, LLC | 381,892 | $2.99M |
| Citadel Advisors LLC | 14,224 | $111.0K |
| Marshall Wace, LLP | 12,780 | $100.0K |
| Cutler Group LP | 32 | $0 |